Compare

Pulmatrix, Inc. vs Cadrenal Therapeutics, Inc. vs Protagenic Therapeutics, Inc.new vs International Stem Cell Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearPulmatrix, Inc.
PULM
Cadrenal Therapeutics, Inc.
CVKD
Protagenic Therapeutics, Inc.new
PTIXRevenue covers only part of its income (partial revenue)
International Stem Cell Corp
ISCO
Year ended2025-12-312025-12-312026-03-312025-12-31
Revenuen/an/an/a$9.10M
Revenue growth (YoY)n/an/an/a+0.2%
Gross marginn/an/an/a55.7% (computed)
Operating marginn/an/an/a-2.9%
Net marginn/an/an/a-4.6%
Net income-$5.16M-$13.24M$1.37M-$418.0K
EPS (Diluted)-$1.41-$6.64$0.59-$0.05
Operating cash flow-$5.43M-$12.60M-$2.81M$8.0K
Free cash flown/a-$12.61M-$2.81M-$35.0K
Cash & equivalents$4.09M$4.01Mn/an/a
Total assets$4.14M$4.33M$3.65M$4.82M
Total liabilities$329.0K$1.59M$1.03M$4.58M
Shareholders' equity$3.81M$2.74M$2.62M-$4.06M
Return on year-end equity-135.5%-483.3%52.2%n/a
Shares outstanding3.65M2.34M1.81M8.00M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearPulmatrix, Inc.Cadrenal Therapeutics, Inc.Protagenic Therapeutics, Inc.newInternational Stem Cell Corp
Latest$7.81M
Ended 2024-12-31
n/an/a$9.10M
Ended 2025-12-31
1 year earlier$7.30M
Ended 2023-12-31
n/an/a$9.09M
Ended 2024-12-31
2 years earlier$6.07M
Ended 2022-12-31
n/an/a$7.79M
Ended 2023-12-31
3 years earlier$5.17M
Ended 2021-12-31
n/an/a$8.18M
Ended 2022-12-31
4 years earlier$12.63M
Ended 2020-12-31
n/an/a$7.18M
Ended 2021-12-31